Drug Trial Radar · NCT02699099
Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.
Last checked: Nov 19, 2026Latest source record: Sep 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
699
Actual
Start
May 10, 2017
Primary completion
Mar 14, 2018
Study completion Oct 7, 2020
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 6 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles, rubella and yellow fever vaccines to children aged 6 months at the first vaccination.
Conditions
- Malaria
- Malaria Vaccines
Interventions
Vitamin ADietary supplement
Oral administration of Vitamin A (1 dose)
Candidate Plasmodium falciparum malaria vaccineBiological
Intramuscular administration of SB257049 vaccine (4 doses)
MR-VacBiological
Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
StamarilBiological
Intramuscular injection of a yellow fever (YF) vaccine (1 dose)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anti-Circumsporozoite (Anti-CS) Antibody Concentrations, One Month Post Dose 3 of SB257049 (Primary Analysis)Time frame: At one month post Dose 3 of SB257049 (Month 4)
- Anti-CS Antibody Concentrations, One Month Post Dose 3 of SB257049 (Study End Analysis)Time frame: At one month post Dose 3 of SB257049 (Month 4)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Kintampo, Ghana
GSK Investigational Site
Kumasi, Ghana
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.